Rendering the leukemia cell susceptible to attack

New England Journal of Medicine

Volumn 361, Issue 13, 2009, Pages 1307-1309

  Sipkins, Dorothy A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMATINIB;

APLASTIC ANEMIA; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL CYCLE; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; HEMATOPOIETIC STEM CELL; KIDNEY CARCINOMA; LEUKEMIA CELL; MELANOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; PROTEIN-TYROSINE KINASES;

EID: 70349445232     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr0904291     Document Type: Article

References (5)

1. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264
2. Essers MAG, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009;458:904-908
3. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-667
4. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 1996;87:4149-4157 (Pubitemid 26152259)
5. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60. (Pubitemid 46053043)